We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Atherectomy Drill Clears Clogged Vasculature of Thrombi and Deposits

By HospiMedica International staff writers
Posted on 22 Dec 2009
An innovative vascular drill for percutaneous revascularization of clogged blood vessels treats the entire spectrum of disease found in the peripheral artery disease (PAD) patient.

The Jetstream G2 NXT drill consists of a sterile, single-use catheter and control pod and a reusable, compact console that mounts to a standard intravenous (IV) stand. More...
An expandable cutting tip safely debulks and preemptively removes both hard and soft plaque, as well as calcium, thrombus, and fibrotic lesions. A highly efficient aspiration port located proximally to the cutting blades continually removes excised tissue and thrombus from the treatment site to a collection bag located on the console. A fully recessed masticating system within the aspiration port helps break the aspirated material into smaller pieces before removal, providing significant benefits for the treating physician and patient, while ensuring no contact with the artery walls. The distal portion of the catheter also possesses infusion ports that provide continuous sterile saline during the atherectomy procedure; an active aspiration safety feature minimizes the risk of distal embolization.

The Jetstream G2 NXT vascular drill is a product of Pathway Medical Technologies (Kirkland, WA, USA), and has been received both the U.S. Food and Drug Administration (FDA) and the European Community (CE) marking of approval. The system is intended for use in atherectomy in upper and lower extremity peripheral arteries over 3 mm in diameter; it is not intended for use in coronary, carotid, iliac, or renal vasculature.

"CE marking is an important achievement for Pathway as we look forward to entering the European market and making a significant impact on a new marketplace,” said Paul Buckman, CEO and President of Pathway Medical Technologies. "We are excited about the opportunity to provide a new physician population with the latest PAD innovation and expanding on our promise to deliver the most effective, minimally invasive treatment for a condition that affects more than 27 million people in Europe and North America.”

Percutaneous revascularization is becoming a viable alternative to surgery in the treatment of PAD. A variety of methods employed to restore circulation to the lower extremities, such as balloon angioplasty, stents, laser atherectomy, and plaque excision.

The advantages of percutaneous techniques include less procedure time, ease of use, faster patient recovery, decreased systemic complications, repeatability in light of new occlusions and hope for nonsurgical candidates.

Related Links:

Pathway Medical Technologies




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.